Elite Pharmaceuticals, Inc.
ELTP
$0.40
-$0.021-4.99%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -7.56% | 33.36% | 109.39% | 107.71% | 67.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.56% | 33.36% | 109.39% | 107.71% | 67.99% |
| Cost of Revenue | -2.97% | 38.56% | 144.20% | 89.04% | 96.22% |
| Gross Profit | -13.09% | 27.15% | 78.39% | 135.90% | 43.14% |
| SG&A Expenses | 58.72% | 47.60% | 20.56% | 193.57% | 46.87% |
| Depreciation & Amortization | 25.91% | 28.45% | 29.67% | 15.46% | 8.12% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.50% | 25.86% | 102.48% | 62.79% | 64.67% |
| Operating Income | -68.92% | 80.99% | 141.20% | 4,062.38% | 80.32% |
| Income Before Tax | -11,196.71% | -248.32% | -34.62% | 332.85% | -103.13% |
| Income Tax Expenses | 129.88% | 108.59% | 49.68% | -457.05% | -2,137.15% |
| Earnings from Continuing Operations | -1,641.89% | -173.90% | -46.07% | 370.55% | -76.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,641.89% | -173.90% | -46.07% | 370.55% | -76.22% |
| EBIT | -68.92% | 80.99% | 141.20% | 4,062.38% | 80.32% |
| EBITDA | -60.52% | 73.36% | 122.23% | 1,545.84% | 70.52% |
| EPS Basic | -1,557.14% | -170.07% | -45.45% | 375.00% | -75.86% |
| Normalized Basic EPS | -463.64% | -229.41% | -37.50% | 500.00% | -191.67% |
| EPS Diluted | -1,557.14% | -203.00% | -45.45% | 106.25% | -75.86% |
| Normalized Diluted EPS | -463.64% | -229.41% | -37.50% | 500.00% | -191.67% |
| Average Basic Shares Outstanding | 5.27% | 5.36% | 5.36% | 0.47% | 0.08% |
| Average Diluted Shares Outstanding | 4.28% | 4.80% | 6.08% | 1.99% | 1.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |